Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

The need for validation of large administrative databases: Veterans Health Administration ICD-9CM coding of exudative age-related macular degeneration and ranibizumab usage.

Latkany P, Duggal M, Goulet J, Paek H, Rambo M, Palmisano P, Levin W, Erdos J, Justice A, Brandt C.

J Ocul Biol Dis Infor. 2010 Jul 9;3(1):30-4. doi: 10.1007/s12177-010-9052-4.

2.
3.

The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity.

Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group.

Ophthalmology. 2014 May;121(5):1092-101. doi: 10.1016/j.ophtha.2013.11.031. Epub 2014 Jan 23.

4.

Accuracy of coding for possible warfarin complications in hospital discharge abstracts.

Arnason T, Wells PS, van Walraven C, Forster AJ.

Thromb Res. 2006;118(2):253-62. Epub 2005 Aug 2.

PMID:
16081144
5.

PTSD diagnoses among Iraq and Afghanistan veterans: comparison of administrative data to chart review.

McCarron KK, Reinhard MJ, Bloeser KJ, Mahan CM, Kang HK.

J Trauma Stress. 2014 Oct;27(5):626-9. doi: 10.1002/jts.21961.

PMID:
25322891
6.

The association of enzymatic and non-enzymatic antioxidant defense parameters with inflammatory markers in patients with exudative form of age-related macular degeneration.

Čolak E, Ignjatović S, Radosavljević A, Žorić L.

J Clin Biochem Nutr. 2017 Mar;60(2):100-107. doi: 10.3164/jcbn.16-30. Epub 2017 Feb 8.

7.

Ranibizumab and risk of hospitalisation for ischaemic stroke and myocardial infarction in patients with age-related macular degeneration: a self-controlled case-series analysis.

Pratt NL, Ramsay EN, Kemp A, Kalisch-Ellett LM, Shakib S, Caughey GE, Ryan P, Graves S, Roughead EE.

Drug Saf. 2014 Dec;37(12):1021-7. doi: 10.1007/s40264-014-0231-2.

8.

Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.

Park SS, Daftari I, Phillips T, Morse LS.

Retina. 2012 May;32(5):956-66. doi: 10.1097/IAE.0b013e31822a8d6a.

PMID:
22183743
9.

Accuracy of administrative coding in identifying hip and knee primary replacements and revisions.

Daneshvar P, Forster AJ, Dervin GF.

J Eval Clin Pract. 2012 Jun;18(3):555-9. doi: 10.1111/j.1365-2753.2010.01622.x. Epub 2011 Jan 11.

PMID:
21223460
10.

CYP4F2 (rs2108622) Gene Polymorphism Association with Age-Related Macular Degeneration.

Sakiene R, Vilkeviciute A, Kriauciuniene L, Balciuniene VJ, Buteikiene D, Miniauskiene G, Liutkeviciene R.

Adv Med. 2016;2016:3917916. doi: 10.1155/2016/3917916. Epub 2016 Aug 29.

11.

Intravitreal Ranibizumab in Daily Clinical Practice for Age-Related Macular Degeneration: Treatment of Exudative Age-Related Macular Degeneration in Real Life.

Cazet-Supervielle A, Gozlan J, Cabasson S, Boissonnot M, Manic H, Leveziel N.

Ophthalmologica. 2015;234(1):26-32. doi: 10.1159/000430470. Epub 2015 Jun 19.

PMID:
26111575
12.

Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting.

Boulanger-Scemama E, Querques G, About F, Puche N, Srour M, Mane V, Massamba N, Canoui-Poitrine F, Souied EH.

J Fr Ophtalmol. 2015 Sep;38(7):620-7. doi: 10.1016/j.jfo.2014.11.015. Epub 2015 Apr 23.

13.

Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.

Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E, Bhatia S, Patel P, Nguyen M, Houranieh A.

Am J Ophthalmol. 2009 Dec;148(6):875-82.e1. doi: 10.1016/j.ajo.2009.07.009. Epub 2009 Oct 2.

PMID:
19800611
14.

Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab.

Bressler NM, Chang TS, Varma R, Suñer I, Lee P, Dolan CM, Ward J, Ianchulev T, Fine J.

Ophthalmology. 2013 Jan;120(1):160-8. doi: 10.1016/j.ophtha.2012.07.027. Epub 2012 Sep 23.

PMID:
23009891
15.

Improving discharge data fidelity for use in large administrative databases.

Gologorsky Y, Knightly JJ, Lu Y, Chi JH, Groff MW.

Neurosurg Focus. 2014 Jun;36(6):E2. doi: 10.3171/2014.3.FOCUS1459.

PMID:
24881634
16.

Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.

Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, Guiberteau B, Quentel G.

Am J Ophthalmol. 2009 Sep;148(3):409-13. doi: 10.1016/j.ajo.2009.04.001. Epub 2009 May 24.

PMID:
19477713
17.
18.

Exploration of ICD-9-CM coding of chronic disease within the Elixhauser Comorbidity Measure in patients with chronic heart failure.

Garvin JH, Redd A, Bolton D, Graham P, Roche D, Groeneveld P, Leecaster M, Shen S, Weiner MG.

Perspect Health Inf Manag. 2013 Oct 1;10:1b. eCollection 2013.

20.

FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity.

Monés J, Biarnés M, Trindade F, Casaroli-Marano R.

Graefes Arch Clin Exp Ophthalmol. 2012 Dec;250(12):1737-44. doi: 10.1007/s00417-012-2009-5. Epub 2012 Apr 15.

Supplemental Content

Support Center